Molecular mechanisms of CD40 signaling

Archivum Immunologiae et Therapiae Experimentalis

Volumn 49, Issue 2, 2001, Pages 129-137

  Bishop, Gail A ^a,b   Hostager, Bruch S ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

B cell; CD40; Lymphocyte activation; Signal transduction; Tumor necrosis family receptor family

Indexed keywords

CD40 ANTIGEN; PHOSPHOTRANSFERASE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; B LYMPHOCYTE; CELL MEMBRANE; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOLOGY; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD40; B-LYMPHOCYTES; CELL MEMBRANE; ENZYME ACTIVATION; HUMANS; PHOSPHOTRANSFERASES; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 0004791415     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. ALTENBURG A., BALDUS S. E., SMOLA H., PFISTER H. and HESS S. (1999): CD40L-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-γ. J. Immunol., 162, 4140-4147.
2. BACCAM M. and BISHOP G. A. (1999): CD154, but not anti-CD40 mAbs, induces NF-κB independent B cell IL-6 production. Eur. J. Immunol., 29, 3855-3866.
3. + T cells via CD40L. Proc. Natl. Acad. Sci. USA, 94, 599-603.
4. BAUD V., LIU Z., BENNETT B., SUZUKI N., ZIA Y. and KARIN M. (1999): Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev., 13, 1297-1308.
5. BEG A. A., SHA W. C., BRONSON R. T., GHOSH S. and BALTIMORE D. (1995): Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature, 376, 167-170.
6. BENNETT S. R. M., CARBONE F. R., KARAMALIS F., FLAVELL R. A., MILLER J. F. A. P. and HEATH W. R. (1998): Help for cytotoxic T cell responses is mediated by CD40 signalling. Nature, 393, 178-180.
7. BERBERICH I., SHU G. L. and CLARK E. A. (1994): Cross-linking CD40 on B cells rapidly activates nuclear factor-κB. J. Immunol., 153, 4357-4366.
8. BIANCONE L., CANTALUPPI V., BOCCELLINO M., DEL SORBO L., RUSSO S., ALBINI A., STAMENKOVIC I. and CAMUSSI G. (1999): Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma. J. Immunol., 163, 6201-6208.
9. CALLARD R. E., ARMITAGE R. J., FANSLOW W. C. and SPRIGGS M. K. (1993): CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol. Today, 14, 559-564.
10. + T lymphocytes. J. Immunol., 152, 1523-1531.
11. CELLA M., SCHEIDEGGER D., PALMER-LEHMANN K., LANE P., LANZAVECCHIA A. and ALBER G. (1996): Ligation of CD40 on dendritic cells triggers production of high levels of IL-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med., 184, 747-752.
12. CHAUDHURI A., ORME S., EILAM S. and CHERAYIL B. J. (1997): CD40-mediated signals inhibit the binding of TRAF2 to the CD40 cytoplasmic domain. J. Immunol., 159, 4244-4251.
13. CHENG G., CLEARY A. M., YE Z., HONG D. I., LEDERMAN S. and BALTIMORE D. (1995): Involvement of CRAFI, a relative of TRAF, in CD40 signaling. Science, 267, 1494-1498.
14. DERIJARD B., RAINGEAUD J., BARRETT T., WU I.-H., HAN J., ULEVITCH R. J. and DAVIS R. J. (1995): Independent human MAPK signal transduction pathways defined by MEK and MKK isoforms. Science, 267, 682-685.
15. DHEIN J., WALCZAK H., BÖUMLER C., DEBATIN K.-M. and KRAMMER P. H. (1995): Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature, 373, 438-441.
16. DURIE F. H., ARUFFO A., LEDBETTER J., CRASSI K. M., GREEN W. R., FAST L. D. and NOELLE R. J. (1994): Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J. Clin. Invest., 94, 1333-1338.
17. DURIE F. H., FAVA R. A., FOY T. M., ARUFFO A. A., LEDBETTER J. A. and NOELLE R. J. (1993): Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science, 261, 1328-1330.
18. FRANCIS D. A., KARRAS J. G., KE X., SEN R. and ROTHSTEIN T. L. (1995): Induction of the transcription factors NF-κB, AP-1 and NF-AT during B cell stimulation through the CD40 receptor. Int. Immunol., 7, 151-161.
19. FRANZOSO G., CARLSON L., POLJAK L., SHORES E. W., EPSTEIN S., LEONARDI A., GRINBERG A., TRAN T., SCHARTON-KERSTEN T., ANVER M., LOVE P., BROWN K. and SIEBENLIST U. (1998): Mice deficient in NF-κB/p52 present with defects in humoral responses, GC reactions, and splenic microarchitecture. J. Exp. Med., 187, 147-159.
20. FUNAKOSHI S., LONGO D. L., BECKWITH M., CONLEY D. K., TSARFATY G., TSARFATY I., ARMITAGE R. J., FANSLOW W. C., SPRIGGS M. K. and MURPHY W. J. (1994): Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood, 83, 2787-2794.
21. GARCEAU N., KOSAKA Y., MASTERS S., HAMBOR J., SHINKURA R., HONJO T. and NOELLE R. J. (2000): Lineage-restriced function of NIK in transducing signals via CD40. J. Exp. Med., 191, 381-385.
22. GAUCHAT J.-F., HENCHOZ S., FATTAH D., MAZZEI G., AUBRY J.-P., JOMOTTE T., DASH L., PAGE K., SOLARI R., ALDEBERT D., CAPRON M., DAHINDEN C. and BONNEFOY J.-Y. (1995): CD40L is functionally expressed on human eosinophils. Eur. J. Immunol., 25, 863-865.
23. GERRITSE K., LAMAN J. D., NOELLE R. J., ARUFFO A., LEDBETTER J. A., BOERSMA W. J. A. and CLAASSEN E. (1996): CD40-CD40L interactions in EAE and MS. Proc. Natl. Acad. Sci. USA, 93, 2499-2504.
24. GOLDSTEIN M. D. and WATTS T. H. (1996): Identification of distinct domains in CD40 involved in B7-1 induction or growth inhibition. J. Immunol., 157, 2837-2843.
25. GRAMMER A. C., SWANTEK J. L., MCFARLAND R. D., MIURA Y., GEPPERT T. and LIPSKY P. E. (1998): TRAF3 signaling mediates activation of p38 and JNK, cytokine secretion, and Ig production following ligation of CD40 on human B cells. J. Immunol., 161, 1183-1193.
26. GRUSS H.-J., HIRSCHSTEIN D., WRIGHT B., ULRICH D., CALIGIURI M. A., BARCOS M., STROCKBINE L., ARMITAGE R. J. and DOWER S. K. (1994): Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood, 84, 2305-2314.
27. HARA T., MURAKAMI M., MAEDA H., HIBI M. and UEDE T. (1997): Involvement of a common 10-amino acid segment in the cytoplasmic region of CD40 but different MAP kinases in different CD40-mediated responses. Biochem. Biophys. Res. Commun., 233, 187-192.
28. - dendritic cells to provide tumor protection is rescued by CD40 ligation. J. Immunol., 163, 77-81.
29. HOLLENBAUGH D., MISCHEL-PETTY N., EDWARDS C. P., SIMON J. C., DENFELD R. W., KIENER P. A. and ARUFFO A. (1995): Expression of functional CD40 by vascular endothelial cells. J. Exp. Med., 182, 33-40.
30. HORNUNG M., LINDEMANN D., KRAUS C., PETERS A. and BERBERICH I. (1998): The CD40 TRAF family member interacting motif carries the information to rescue WEHI 231 cells from anti-IgM-induced growth arrest. Eur. J. Immunol., 28, 3812-3823.
31. HOSTAGER B. S. and BISHOP G. A. (1999): Cutting Edge: contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-mediated B lymphocyte activation. J. Immunol., 162, 6307-6311.
32. HOSTAGER B. S., CATLETT I. M. and BISHOP G. A. (2000): Recruitment of CD40, TRAF2 and TRAF3 to membrane microdomains during CD40 signaling. J. Biol. Chem., 275, 15392-15398.
33. HOSTAGER B. S., HSING Y., HARMS D. E. and BISHOP G. A. (1996): Different CD40-mediated signaling events require distinct CD40 structural features. J. Immunol., 157, 1047-1053.
34. HSING Y. and BISHOP G. A. (1999): Requirement for NF-κB activation by a distinct subset of CD40-mediated effector functions in B lymphocytes. J. Immunol., 162, 2804-2811.
35. HSING Y., HOSTAGER B. S. and BISHOP G. A. (1997): Characterization of CD40 signaling determinants regulating NF-κB activation in lymphocytes. J. Immunol., 159, 4898-4906.
36. HU H. M., O'ROURKE K., BOGUSKI M. S. and DIXIT V. M. (1994): A novel RING finger protein interacts with the cytoplasmic domain of CD40. J. Biol. Chem., 269, 30069-30072.
37. ICHIJO H., NISHIDA E., IRIE K., TEN DIJKE P., SAITOH M., MORIGUCHI T., TAKAGI M., MATSUMOTO K., MIYAZONO K. and GOTOH Y. (1997): Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SPAK/JNK and p38 signaling pathways. Science, 275, 90-94.
38. INUI S., KAISHO T., KIKUTANI H., STAMENKOVIC I., SEED B., CLARK E. A. and KISHIMOTO T. (1990): Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40. Eur. J. Immunol., 20, 1747-1753.
39. ISHIDA T., MIZUSHIMA S., AZUMA S., KOBAYASHI N., TOJO T., SUZUKI K., AIZAWA S., WATANABE T., MOSIALOS G., KIEFF E., YAMAMOTO T. and INOUE J. (1996): Identification of TRAF6, a novel TRAF protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J. Biol. Chem., 271, 28745-28748.
40. ISHIDA T., TOJO T., AOKI T., KOBAYASHI N., OHISHI T., WATANABE T., YAMAMOTO T. and INOUE J.-I. (1996): TRAF5, a novel TNF-R-associated factor family protein, mediates CD40 signaling. Proc. Natl. Acad. Sci. USA, 93, 9437-9442.
41. JALUKAR S. V., HOSTAGER B. S. and BISHOP G. A. (2000): Characterization of the roles of TRAF6 in CD40-mediated B lymphocyte effector functions. J. Immunol., 164, 623-630.
42. KARMANN K., HUGHES C. C. W., SCHECHNER J., FANSLOW W. C. and POBER J. S. (1995): CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl. Acad. Sci. USA, 92, 4342-4346.
43. KAWABE T., NAKA T., YOSHIDA K., TANAKA T., FUJIWARA H., SUEMATSU S., YOSHIDA N., KISHIMOTO T. and KIKUTANI H. (1994): The immune responses in CD40-deficient mice: impaired Ig class switching and germinal center formation. Immunity, 1, 167-178.
44. KEHRY M. R. (1996): CD40-mediated signaling in B cells. J. Immunol., 156, 2345-2348.
45. KENNEDY M. K., MOHLER K. M., SHANEBECK K. D., BAUM P. R., PICHA K. S., OTTEN-EVANS C. A., JANEWAY C. A. and GRABSTEIN K. H. (1994): Induction of B cell costimulatory function by recombinant CD40 ligand. Eur. J. Immunol., 24, 116-123.
46. KLUTH B., HESS S., ENGELMANN H., SCHAFNITZEL S., REITH-MÜLLER G. and FEUCHT H. E. (1997): Endothelial expression of CD40 in renal cell carcinoma. Cancer Res., 57, 891-899.
47. KOCH F., STANZL U., JENNEWEIN P., JANKE K., HEUFLER C., KÄMPGEN E., ROMANI N. and SCHULER G. (1996): High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med., 184, 741-746.
48. KOOPMAN G., KEEHNEN R. M. J., LINDHOUR E., NEWMAN W., SHIMIZU Y., VAN SEVENTER G. A., DE GROOT C. and PALS S. T. (1994): Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J. Immunol., 152, 3760-3767.
49. KUHNÉ M. R., ROBBINS M., HAMBOR J. E., MACKEY M. F., KOSAKA Y., NISHIMURA T., GIGLEY J. P., NOELLE R. J. and CALDERHEAD D. M. (1997): Assembly and regulation of the CD40 receptor complex in human B cells. J. Exp. Med., 186, 337-342.
50. LAM E. W.-F., GLASSFORD J., VAN DER SMAN J., BANERJI L., PIZZEY A. R., THOMAS S. B. and KLAUS G. G. B. (1999): Modulation of E2F activity in primary mouse B cells following stimulation via surface IgM and CD40 receptors. Eur. J. Immunol., 29, 539-547.
51. LEE F. S., HAGLER J., CHEN Z. J. and MANIATIS T. (1997): Activation of the IκBα kinase complex by MEKK1, a kinase of the JNK pathway. Cell, 88, 213-222.
52. LEE S. Y., REICHLIN A., SANTANA A., SOKOL K. A., NUSSENZWEIG M. C. and CHOI Y. (1997): TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity, 7, 701-713.
53. LENS S. M. A., TESSELAAR K., DEN DRIJVER B. F. A., VAN OERS M. H. J. and VAN LIER R. A. W. (1996): A dual role for both CD40L and TNF-α in controlling human B cell death. J. Immunol., 156, 507-514.
54. LIN S.-C. and STAVNEZER J. (1996): Activation of NF-κB/Rel by CD40 engagement induces the mouse germ line Ig Cγ1 promoter. Mol. Cell. Biol., 16, 4591-4603.
55. LINEHAN L. A., WARREN W. D., THOMPSON P. A., GRUSBY M. J. and BERTON M. T. (1998): STAT6 is required for IL-4-induced germline Ig gene transcription and switch recombination. J. Immunol., 161, 302-310.
56. LING L., CAO Z. and GOEDDEL D. V. (1998): NF-κB inducing kinase activates IKK-a by phosphorylation of Ser-176. Proc. Natl. Acad. Sci. USA, 95, 3792-3797.
57. LOMAGA M. A., YEH W. C., SAROSI I., DUNCAN G. S., FURLONGER C., Ho A., MORONY S., CAPPARELLI C., VAN G. KAUFMAN S., VAN DEN HEIDEN A., ITIE A., WAKEHAM A., KHOO W., SASAKI T., CAO Z., PENNINGER J. M., PAIGE C. J., LACEY D. L., DUNSTAN C. R., BOYLE W. J., GOEDDEL D. V. and MAK T. W. (1999): TRAF6 deficiency results in osteopetrosis and defective IL-1, CD40, and LPS signaling. Genes Dev., 13, 1015-1024.
58. MACKEY M. F., GUNN J. R., MALISZEWSKI C., KIKUTANI H., NOELLE R. J. and BARTH R. J. (1998): DC require maturation via CD40 to generate protective antitumor immunity. J. Immunol., 161, 2094-2098.
59. MALININ N. L., BOLDIN M. P., KOVALENKO A. V. and WALLACH D. (1997): MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature, 385, 540-544.
60. MOHAN C., SHI Y., LAMAN J. D. and DATTA S. K. (1995): Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol., 154, 1470-1480.
61. MURPHY W. J., FUNAKOSHI S., BECKWITH M., RUSHING S. E., CONLEY D. K., ARMITAGE R. J., FANSLOW W. C., RAGER H. C., TAUB D. D., RUSCETTI F. W. and LONGO D. L. (1995): Antibodies to CD40 prevent EBV-mediated human B-cell lymphomagenesis in SCID mice given human peripheral blood lymphocytes. Blood, 86, 1946-1953.
62. NGUYEN L. T., DUNCAN G. S., MIRTSOS C., NG M., SPEISER D. E., SHAHINIAN A., MARINO M. W., MAK T. W., OHASHI P. S. and YEH W. C. (1999): TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses. Immunity, 11, 379-389.
63. PAULIE S., EHLIN-HENRIKSSON B., MELLSTEDT H., KOHO H., BEN-AISSA H. and PERLMANN P. (1985): A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol. Immunother., 20, 23-28.
64. RANHEIM E. A. and KIPPS T. J. (1995): TNF-α facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell. Immunol., 161, 226-235.
65. REN C. L., MORIO T., FU S. M. and GEHA R. S. (1994): Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase Cγ2. J. Exp. Med., 179, 673-680.
66. REVY P., HIVROZ C., ANDREU G., GRABER P., MARTINACHE C., FISCHER A. and DURANDY A. (1999): Activation of the Jak3-STAT5a pathway after CD40 triggering of human monocytes but not of resting B cells. J. Immunol., 163, 787-793.
67. RIECKMANN P., D'ALLESSANDRO F., NORDAN R. P., FAUCI A. S. and KEHRL J. H. (1991): IL-6 and TNF-α. Autocrine and paracrine cytokines involved in B cell function. J. Immunol., 146, 3462-3468.
68. ROKHLIN O. W., BISHOP G. A., HOSTAGER B. S., WALDSCHMIDT T. J., SIDORENKO S. P., PAVLOFF N., KIEFER M. C., UMANSKY S. R., GLOVER R. A. and COHEN M. B. (1997): Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res., 57, 1758-1768.
69. ROTHE M., SARMA V., DIXIT V. M. and GOEDDEL D. V. (1995): TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science, 269, 1424-1427.
70. SANCHEZ I., HUGES R. T., MAYER B. J., YEE K., WOODGETT J. R., AVRUCH J., KYRIAKIS J. M. and ZON L. I. (1994): Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-jun. Nature, 372, 794-798.
71. SCHOENBERGER S. P., TOES R. E. M., VAN DER VOORT E. I. H., OFFRINGA R. and MELIEF C. J. M. (1998): T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 393, 480-483.
72. SHEPHERD D. M. and KERKVLIET N. I. (1999): Disruption of CD154: CD40 blocks generation of allograft immunity without affecting APC activation. J. Immunol., 163, 2470-2477.
73. SHI C., LEONARDI A., KYRIAKIS J., SIEBENLIST U. and KEHRL J. H. (1999): TNF-mediated activation of the SAPK pathway: TRAF2 recruits and activates germinal center kinase related. J. Immunol., 163, 3279-3285.
74. SHINKURA R., KITADA K., MATSUDA F., TASHIRO K., IKUTA K., SUZUKI M., KOGISHI K., SERIDAWA T. and HONJO T. (1999): Alymphoplasia is caused by a point mutation in the mouse gene encoding NIK. Nat. Genet., 22, 74-77.
75. SHU U., KINIWA M., WU C. Y., MALISZEWSKI C., VEZZIO N., HAKIMI J., GATELY M. and DELESPESSE G. (1995): Activated T cells induce IL-12 production by monocytes via CD40-CD40L interaction. Eur. J. Immunol., 25, 1125-1128.
76. H transcription, and Ig class switching. J. Immunol., 156, 183-191.
77. SONG H. Y., RÉGNIER C. H., KIRSCHNING C. J., GOEDDEL D. V. and ROTHE M. (1997): TNF-mediated kinase cascades: bifurcation of NF-κB and JNK/SAPK pathways at TRAF2. Proc. Natl. Acad. Sci. USA, 94, 9792-9796.
78. SUTHERLAND C. L., KREBS D. L. and GOLD M. R. (1999): An 11-amino acid sequence in the cytoplasmic domain of CD40 is sufficient for activation of JNK, activation of MAPKAP kinase-2, phosphorylation of IκBα, and protection of WEHI-231 cells from anti-IgM-induced growth arrest. J. Immunol., 162, 4720-4730.
79. TAKEUCHI M., ROTHE M. and GOEDDEL D. V. (1996): Anatomy of TRAF2. Distinct domains for NF-κB activation and association with TNF signaling proteins. J. Biol. Chem., 271, 19935-19942.
80. TAN J., TWON T., PARIS D., MORI T., SUO Z., CRAWFORD F., MATTSON M. P., FLAVELL R. A. and MULLAN M. (1999): Microglial activation resulting from CD40-CD40L interaction after β-amyloid stimulation. Science, 286, 2352-2355.
81. URASHIMA M., CHAUHAN D., UCHIYAMA H., FREEMAN G. J. and ANDERSON K. C. (1995): CD40 ligand triggered IL-6 secretion in multiple myeloma. Blood, 85, 1903-1912.
82. VAN DEN OORD J., MAES A., STAS M., NUYTS J., BATTOCCHIO S., KASRAN A., GARMYN M., DE WEVER I. and DE WOLF-PEETERS C. (1997): CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am. J. Pathol., 149, 1953-1961.
83. VAN KOOTEN C. and BANCHEREAU J. (1996): CD40-CD40L: A multifunctional receptor-ligand pair. Adv. Immunol., 61, 1-77.
84. WAKATSUKI Y., NEURATH M. F., MAX E. E. and STROBER W. (1994): The B cell-specific transcription factor BSAP regulates B cell proliferation. J. Exp. Med., 179, 1099-1108.
85. WEIH F., CARRASCO D., DURHAM S. K., BARTON D. S., RIZZO C. A., RYSECK R., LIRA S. A. and BRAVO R. (1995): Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell, 80, 331-340.
86. XU Y., CHENG G. and BALTIMORE D. (1996): Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity, 5, 407-415.
87. XU J., FOY T. M., LAMAN J. D., ELLIOTT E. A., DUNN J. J., WALDSCHMIDT T. J., ELSEMORE J., NOELLE R. J. and FLAVELL R. A. (1994): Mice deficient for the CD40 ligand. Immunity, 1, 423-431.
88. YAN M., DAI T., DEAK J. C., KYRIAKIS J. M., ZON L. I., WOODGETT J. R. and TEMPLETON D. J. (1994): Activation of SAPK by MEKK1 phosphorylation of its activator SEK1. Nature, 372, 798-800.
89. YEH W., SHAHINIAN A., SPEISER D., KRAUNUS J., BILLIA F., WAKEHAM A., DE LA PAMPA J. L., FERRICK D., HUM B., ISCOVE N., OHASHI P., ROTHE M., GOEDDEL D. V. and MAK T. W. (1997): Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity, 7, 715-725.
90. YELLIN M. J., SINNING J., COVEY L. R., SHERMAN W., LEE J. J., GLICKMAN-NIR E., SIPPEL K. C., ROGERS J., CLEARY A. M., PARKER M., CHESS L. and LEDKRMAN S. (1994): T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells of CLL B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J. Immunol., 153, 666-674.
91. YUASA T., OHNO S., KEHRL J. H. and KYRIAKIS J. M. (1998): TNF signaling to SAPK/JNK and p38. Germinal center kinase couples TRAF2 to MAPK/ERK kinase kinase 1 and SAPK while RIP associates with a MAPKKK upstream of MKK6 and p38. J. Biol. Chem., 273, 22681-22692.
92. H transcription and Ig class switching. J. Immunol., 159, 3133-3139.